AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at the American Association for Cancer Research (AACR) Annual Meeting 2025. These awards highlight significant achievements in translational research and oncology leadership from both early career and internationally renowned scientists and clinicians.
The honors include:
AACR-Daniel...
ASCO: Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
ABSTRACTS: 3000 and 3005
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual...
AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with...
MD Anderson expands breakthrough research campus with groundbreaking of innovative new facility
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’s expansive south campus research park. The building was purposefully built to enable collaborative science and impactful breakthrough discoveries that will accelerate efforts to end cancer.
A $668 million institutional investment will support the construction of MD Anderson’s South Campus Research...
Research identifies new potential hurdle for nano-based therapies
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective...
MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
MD Anderson celebrates World Cancer Research Day
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...